As of 2024-12-11, the Relative Valuation of Elicera Therapeutics AB (ELIC.ST) is (9.43) SEK. This relative valuation is based on P/E multiples. With the latest stock price at 1.83 SEK, the upside of Elicera Therapeutics AB based on Relative Valuation is -614.1%.
The range of the Relative Valuation is (7.71) - (10.52) SEK.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 11.8x - 17.8x | 14.8x |
| Forward P/E multiples | 13.0x - 21.1x | 17.0x |
| Fair Price | (7.71) - (10.52) | (9.43) |
| Upside | -520.3% - -673.3% | -614.1% |
| Date | P/E |
| 2024-11-29 | -3.10 |
| 2024-11-28 | -2.80 |
| 2024-11-27 | -2.86 |
| 2024-11-26 | -2.88 |
| 2024-11-25 | -2.89 |
| 2024-11-22 | -2.93 |
| 2024-11-21 | -2.97 |
| 2024-11-20 | -3.01 |
| 2024-11-19 | -3.11 |
| 2024-11-18 | -3.17 |
| 2024-11-15 | -3.14 |
| 2024-11-14 | -3.13 |
| 2024-11-13 | -3.32 |
| 2024-11-12 | -3.33 |
| 2024-11-11 | -3.23 |
| 2024-11-08 | -3.03 |
| 2024-11-07 | -3.14 |
| 2024-11-06 | -3.22 |
| 2024-11-05 | -3.33 |
| 2024-11-04 | -3.05 |
| 2024-11-01 | -3.16 |
| 2024-10-31 | -3.19 |
| 2024-10-30 | -3.33 |
| 2024-10-29 | -3.46 |
| 2024-10-28 | -3.41 |
| 2024-10-25 | -3.04 |
| 2024-10-24 | -2.88 |
| 2024-10-23 | -2.62 |
| 2024-10-22 | -2.59 |
| 2024-10-21 | -2.55 |
| 2024-10-18 | -2.58 |
| 2024-10-17 | -2.77 |
| 2024-10-16 | -2.67 |
| 2024-10-15 | -2.68 |
| 2024-10-14 | -2.36 |
| 2024-10-11 | -2.36 |
| 2024-10-10 | -2.36 |
| 2024-10-09 | -2.26 |
| 2024-10-08 | -2.33 |
| 2024-10-07 | -2.55 |
| 2024-10-04 | -2.70 |
| 2024-10-03 | -2.59 |
| 2024-10-02 | -2.66 |
| 2024-10-01 | -2.70 |
| 2024-09-30 | -2.69 |
| 2024-09-27 | -2.53 |
| 2024-09-26 | -2.73 |
| 2024-09-25 | -2.74 |
| 2024-09-24 | -2.64 |
| 2024-09-23 | -2.74 |